

C-Reactive Protein Was an Early Predictor of Postoperative Infectious Complications After Pancreaticoduodenectomy for Pancreatic Cancer

Yosuke Atsumi¹, Toru Aoyama¹, Keisuke Kazama¹, Masaaki Murakawa¹, Manabu Shiozawa¹, Satoshi Kobayashi², Makoto Ueno², Manabu Morimoto², Takashi Oshima³, Norio Yukawa³, Takaki Yoshikawa³, Yasushi Rino³, Munetaka Masuda³, Soichiro Morinaga¹

¹Department of Gastrointestinal Surgery and ²Division of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan

³Department of Surgery, Yokohama City University, Yokohama, Japan

Objective: The study objective was to assess the predictive value of C-reactive protein (CRP) for the early detection of postoperative infectious complications (PICs) after pancreaticoduodenectomy.

Summary of Background Data: The incidence of PICs after pancreaticoduodenectomy still remains high and a clinically relevant problem, despite improvements in the surgical procedure.

Methods: We examined 110 consecutive patients who underwent pancreaticoduodenectomy for primary pancreatic cancer between 2006 and 2014. The predictive value was assessed by estimating the area under the receiver operating characteristic curve (AUC). Clinical and laboratory data, including CRP, were analyzed with univariate and multivariate logistic regression analyses to identify predictors of PICs of grade III or higher according to the Clavien-Dindo classification.

Results: PICs of grade III or higher occurred in 13 patients [11.8%; 95% confidence interval (CI), 6.45%–19.36%]. CRP level on postoperative day 3 (POD 3) was a good predictor of

Corresponding author: Toru Aoyama, Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan.
E-mail: aoyamat@kcch.jp

PICs (AUC, 0.815; 95% CI, 0.651–0.980), showing the highest accuracy among clinical and laboratory data. A cutoff value of 13.2 mg/dL yielded a sensitivity of 0.846 and a specificity of 0.794. On multivariate analysis, a POD 3 CRP level of 13.2 mg/dL or higher (odds ratio, 20.0; 95% CI, 4.07–97.9; $P = 0.002$) was a significant predictor of PICs after pancreaticoduodenectomy.

Conclusions: CRP elevation above 13.2 mg/dL on POD 3 is a significant predictive factor for PICs and should prompt an intense clinical search and therapeutic approach for PICs.

Key words: Pancreaticoduodenectomy – CRP – Infectious complications

Pancreatic cancer is a major cause of cancer death worldwide, with a 5-year survival rate of less than 5%.¹ Pancreaticoduodenectomy (PD) is essential for the cure of pancreatic head cancer.^{2–4} However, the postoperative infectious complication (PIC) rate after PD has been reported to range from 30% to 65%.^{5,6}

Recent studies have demonstrated that the development of PICs decreased patient survival or increased the risk of disease recurrence in various types of malignancies. For instance, Aoyama *et al*⁷ examined 164 patients who underwent curative surgery for pancreatic cancer and classified patients into those with and those without PICs. They found that PICs were a risk factor for pancreatic cancer survival and recurrence.⁷ Moreover, some authors have suggested that the immunologic response against PICs enhanced the viability of undetectable residual tumor cells after surgery, thereby increasing disease recurrence.^{8–10}

C-reactive protein (CRP) is an acute-phase protein, and its short half-life of 19 hours makes it a valuable marker to detect disease activity, inflammatory response, and postoperative recovery.¹¹ Measuring CRP levels is widely available and well established in routine clinical practice because of its low cost, unlike procalcitonin^{12,13} or interleukin 16,^{14,15} other recently described markers of systemic inflammation. The predictive value of postoperative CRP levels to rule out infectious complications after colorectal, gastroesophageal, and pancreatic surgery has been previously assessed, and some of the studies showed a high level of accuracy.^{6,16–24} However, few studies enrolled only patients who underwent PD for pancreatic head cancer.

The aim of the present study was to investigate predictive clinical factors, including CRP, for the early detection of PICs in consecutive patients who had undergone PD for pancreatic head cancer.

Patients and Methods

Patients

The patients were selected from the medical records of 110 consecutive patients who underwent PD for pancreatic cancer at Kanagawa Cancer Center from October 10, 2006, to December 22, 2014, according to the following criteria: (1) a pathologically common type of pancreatic cancer according to the International Union Against Cancer (UICC) TNM 7th edition²⁵; and (2) those who had undergone a gross complete (R0 or R1) resection of pancreatic cancer as initial treatment. The resected specimens were examined histopathologically and staged according to the UICC TNM 7th edition. Patients with other pancreatic and periampullary neoplasms, such as intraductal papillary mucinous neoplasms, cystadenocarcinoma, and endocrine tumors, were excluded.

This study was approved by the Institutional Review Board of the Kanagawa Cancer Center (IRB no. 22epidemiology38). Written informed consent was obtained from all participants prior to surgery.

Surgical procedure

All patients underwent subtotal stomach-preserving PD²⁶ as the standard procedure. Lymph node groups resected en bloc included the anterior pancreatic duodenal lymph nodes, the posterior pancreatic duodenal lymph nodes, nodes in the lower hepatoduodenal ligament, and nodes along the right lateral aspect of the superior mesenteric artery and vein. In our institution, we cut the pancreas using an energy device. The modified Child method²⁷ of reconstruction, which included end-to-side pancreaticojejunostomy and duct-to-mucosa anastomosis with a 5-Fr lost stent tube, was performed with eight 5-0 monofilament absorbable sutures, and approximation of the pancreas stump and jejunal wall using four 3-0

monofilament absorbable interrupted sutures was performed.²⁸ End-to-side hepaticojejunostomy was performed without a stent. Anastomosis between the jejunum and the stomach with antecolic reconstruction was made. Multiple intraperitoneal drains were placed: the first was placed posterior to hepaticojejunostomy, the second was placed in the foramen of Winslow, and the third was placed on the anterior surface of the pancreaticojejunostomy. To prevent hypothermia, a blanket warming system and warming set for intravenous infusion were used.

Perioperative care

In principle, the patients all received the same perioperative care. In brief, the patients were allowed to eat until midnight on the day before the surgery and were required to drink the contents of two 500-mL plastic bottles containing oral rehydration solution until 3 hours before surgery. The nasogastric tube was removed on postoperative day 1 (POD 1) after surgery. Oral intake was initiated on POD 2, beginning with water and an oral nutritional supplement. The patients began to eat solid food on POD 5, starting with rice gruel and soft food and advancing in 3 steps to regular food intake. The patients were discharged when they achieved adequate pain relief and soft food intake, returned to their preoperative mobility level, and exhibited normal laboratory data.

Definition of surgical complications

Complications of grades III to V according to the Clavien-Dindo classification^{29,30} that occurred during hospitalization and/or within 30 days after surgery were retrospectively determined from the patient's record. A pancreatic fistula was defined according to the international study group on pancreatic fistula (ISGPF) criteria.^{31,32} Delayed gastric emptying was defined as a nasogastric tube that remained *in situ* or was reinserted after POD 3 (ISGPS definition).³³ PICs were defined as follows: postoperative pancreatic fistulas (POPFs), leakage of the gastrojejunal or choledochojejunal anastomosis, intraabdominal abscesses, cholangitis, pneumonia, or urinary tract infections. Grades I to II complications were not evaluated in order to exclude the possibility of a description bias in the patient's records. The serum levels of CRP were measured on PODs 1, 3, 5, and 7.

Table 1 Clinicopathologic features of 110 patients

	Value
Patients, N	110
Age, y, median (range)	68 (40–83)
Sex, n (%)	
Male	59 (53.6)
Female	51 (46.4)
BMI, kg/m ² , median (range)	21.71 (15.7–33.73)
Preoperative serum Alb level, g/dL, median (range)	4.0 (3.0–5.0)
ASA-PS, n (%)	
1	14 (12.7)
2	93 (84.5)
3	3 (2.7)
Clinical stage, n (%)	
IA	3 (2.7)
IB	28 (25.5)
IIA	39 (35.5)
IIB	34 (30.9)
III	6 (5.5)
Operative time, min, median (range)	517.5 (198–840)
Blood loss, mL, median (range)	1015 (265–6730)
PICs according to the Clavien-Dindo classification, n (%)	
None, or grade II or lower	97 (88.2)
Grade III or higher	13 (11.8)

Statistical analysis

All statistics analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, it is a modified version of R commander designed to add statistical functions frequently used in biostatistics.³⁴ A two-sided *P* value <0.05 was considered to be significant. Continuous data are presented as the mean ± SD or median with range. The Mann-Whitney test and Fisher exact test were employed to evaluate differences in continuous and categorical variables, respectively. Diagnostic accuracy was determined by the area under the receiver operating characteristic curve (AUC).^{35–37} The optimal cutoff values were determined by maximizing Youden index (sensitivity + specificity – 1). Univariate and multivariate logistic regression analyses were used to identify the clinical risk factors for PICs of grade III or higher according to the Clavien-Dindo classification.

Results

Patient characteristics

The patient characteristics are shown in Table 1. The median age of patients was 68 years (range, 64–73

Table 2 Details of PICs

	Clavien-Dindo classification, n					Total, n (%)
	Grade IIIa	Grade IIIb	Grade IVa	Grade IVb	Grade V	
POPF	6	2	0	1	0	9 (8.2)
Intra-abdominal abscesses	2	0	0	0	0	2 (1.8)
Cholangitis	0	0	0	1	0	1 (0.9)
Leakage of the choledochojejunal anastomosis	1	0	0	0	0	1 (0.9)
Leakage of the gastrojejunal anastomosis	0	0	0	0	0	0 (0)
Pneumonia	0	0	0	0	0	0 (0)
Urinary tract infections	0	0	0	0	0	0 (0)
Surgical site infections	0	0	0	0	0	0 (0)

years), and 51 of 110 patients (46%) were women. The mean body mass index (BMI) and preoperative serum albumin (Alb) level of all patients were 21.7 kg/m² (range, 15.7–33.7 kg/m²) and 4.0 g/dL (range, 3.0–5.0 g/dL), respectively. A total of 107 patients had an American Society of Anesthesiologists Physical Status (ASA-PS) of 1 or 2. The median operative time and the median blood loss were 517.5 minutes (range, 198–840 minutes) and 1015 mL (range, 265–6730 mL), respectively.

Surgical morbidity and mortality

PICs of grade III or higher according to the Clavien-Dindo classification occurred in 13 patients (11.8%). Pancreatic fistula was observed in 8 and abdominal abscess in 2, and no patients died during hospitalization. The details of the complications are shown in Table 2. POPF was the most frequently diagnosed complication, followed by intraabdominal abscess and cholangitis.

Associations between postoperative CRP level and PICs

CRP level peaked on POD 3 in patients with PICs of grade III or higher, at which point the CRP level was significantly higher than that in patients with PICs of grade II or lower. The CRP values from POD 3 through POD 7 were 17.63 ± 8.18 mg/dL on POD 3, 10.55 ± 6.16 mg/dL on POD 5, and 9.56 ± 6.81 mg/dL on POD 7 in patients with PICs of grade III or higher; and 8.91 ± 5.01 mg/dL on POD 3, 4.07 ± 4.44 mg/dL on POD 5, and 3.04 ± 3.35 mg/dL on POD 7 in patients with PICs of grade II or lower. A significant difference in the CRP level on POD 5 ($P < 0.0001$) and POD 7 ($P < 0.0001$) was observed between patients with and without PICs of grade III or higher.

Receiver-operating characteristic analysis evaluated the diagnostic accuracy of CRP level on POD 3

for the occurrence of PICs of grade III or higher, as shown in Fig. 1. The CRP level on POD 3 showed a superior diagnostic accuracy [AUC, 0.817; 95% confidence interval (CI), 0.651–0.980], with an optimal cutoff value of 13.2 mg/dL. The sensitivity was 84.6%, and the specificity was 79.4% when a CRP level of 13.2 mg/dL was set as the cutoff value.

Risk factors for PICs

The results of univariate and multivariate analyses of various clinical factors, such as age, sex, preoperative BMI, Alb level, ASA-PS, operative time, intraoperative blood loss, and POD 3 CRP level for PICs of grade III or higher are shown in Table 2. We used the medians as the cutoff points for BMI, Alb, operative time, and intraoperative blood loss. Multivariate analyses found that only a CRP level on POD 3 of 13.2 mg/dL or higher (odds ratio, 18.5; 95% CI, 2.88–119) was a significant independent predictive factor for PICs after PD among these factors (Table 3). Patients with a CRP level higher than 13.2 mg/dL on POD 3 had a significantly higher POPF (grade III or above) rate than those with lower CRP levels ($P < 0.001$).

Discussion

The present study found that CRP level on POD 3 had a superior diagnostic accuracy for PICs, and the optimal cutoff value for CRP was determined to be 13.2 mg/dL. Moreover, the univariate and multivariate analyses identified CRP level ≥13.2 mg/dL on POD 3 as a significant independent predictive factor for PICs after PD. Therefore, the CRP measurement on POD 3 may be a useful and relevant marker for clinical assessment after PD.

Similar results were observed in previous reports. Warschkow *et al*¹⁶ assessed the diagnostic accuracy of the CRP level for the occurrence of PICs in 280




Fig. 1 Association between postoperative CRP level and PICs.

patients after pancreatic surgery. They reported that the diagnostic sensitivity on POD 4 was 63% (95% CI, 50%–76%), and the specificity was 79% (95% CI, 71%–88%) using a cutoff CRP value of 18.4 mg/dL. In this study, they found that CRP levels had a moderate diagnostic accuracy for PICs after pancreatic surgery. In addition, Welsch *et al*⁶ also reported a moderate accuracy of CRP for PICs. They evaluated 688 patients undergoing pancreatic resections with

pancreaticojejunostomy. They reported that a cutoff CRP value of 14.0 mg/dL on POD 4 yielded a sensitivity of 69.5% and a specificity of 87.1% for PICs. These findings suggested that persistent elevation of CRP after pancreatic resection can indicate the development of inflammatory complications.

In the present study, diagnostic accuracy was determined by the AUC.^{35–37} The optimal cutoff

Table 3 Predictive factors for PICs of grade III or higher

Patient characteristics	No. of patients	Patients with PICs of grade III or higher, n (%)	Univariate analysis			Multivariate analysis		
			Odds ratio	95% CI	P value	Odds ratio	95% CI	P value
Age								
≥75 y	23	2 (8.7)	1	0.29–15.12	1	1	0.23–20.00	0.50
<75 y	87	11 (12.6)	1.51			2.15		
Sex								
Female	51	3 (5.9)	1	0.77–19.39	0.084	1	0.50–17.90	0.23
Male	59	10 (16.9)	3.23			2.99		
BMI								
<22 kg/m ²	58	3 (5.2)	1	1.02–25.88	0.004	1	0.29–8.16	0.61
≥22 kg/m ²	52	10 (19.2)	4.31			1.54		
Preoperative serum Alb level, g/dL								
<4.0 g/dL	50	3 (6.0)	1	0.89–22.8	0.072	1	0.56–16.10	0.20
≥4.0 g/dL	51	10 (19.6)	3.77			3.01		
ASA-PS								
1 or 2	107	12 (11.2)	1	0.062–79.81	0.32	1	0.35–139	0.20
3	3	1 (33.3)	3.88			6.98		
Clinical stage								
IA/IB	31	3 (9.7)	1	0.31–8.19	1	1	0.31–14.29	0.45
IIA/IIB/III	79	10 (12.7)	1.35			2.08		
Operative time								
<520 min	57	6 (10.5)	1	0.34–5.02	0.77	1	0.33–11.11	0.47
≥520 min	53	7 (13.2)	1.29			1.92		
Blood loss								
<1000 mL	53	5 (9.4)	1	0.42–6.52	0.56	1	0.29–9.03	0.58
≥1000 mL	57	8 (14.0)	1.56			1.63		
CRP level on POD 3								
<13.2 mg/dL	79	2 (2.5)	1	4.00–203.68	<0.001	1	3.05–147	0.002
≥13.2 mg/dL	31	11 (35.5)	20.42			21.2		

values were determined by maximizing Youden index (sensitivity + specificity – 1). The estimated optimal cutoff value of 13.2 mg/dL for CRP on POD 3 yielded a positive predictive value of 35.5% (95% CI, 19.2%–54.6%) and a negative predictive value of 97.5% (95% CI, 91.2%–99.7%). The high negative predictive value of 97.5% suggested that the development of PICs can be ruled out when the CRP value on POD 3 is 13.2 mg/dL or lower, whereas the positive predictive value of 35.5% is too low to rule in PICs. The predictive value of postoperative CRP levels to rule out infectious complications after colorectal, gastroesophageal, and pancreatic surgery has been assessed previously, and some studies showed a high level of accuracy,^{6,16,17,22,23,38–42} as shown in Table 4. The receiver operating characteristic analysis indicated that not identical, but similar CRP levels provided the optimal cutoff value to balance the sensitivity and specificity in various gastrointestinal cancer surgeries.

There are several possible reasons why CRP affected the PIC of pancreatic cancer patients. One

possible reason for this association was that lipopolysaccharide release due to bacterial infection and tissue ischemia induced the release of interleukin 6 (and other cytokines), which was the chief stimulator of hepatocellular CRP synthesis. This mechanism was also associated with a higher POPF (grade III or higher) rate in patients with CRP levels above 13.2 mg/dL on POD 3. However, the precise mechanism remains unknown.

Previously, clinicopathologic factors, such as white blood cells (WBCs), procalcitonin, and interleukin 6, were reported to be significant risk factors that could be used to predict PICs after PD. For instance, WBC count has been reported to have a poor diagnostic accuracy for detecting PICs, because the counts do not differ significantly from uneventful courses until later stages. Warschkow *et al*¹⁸ evaluated 1187 patients who underwent colorectal cancer surgery and assessed the diagnostic accuracy of the WBC count on POD 3 using a receiver operating characteristic analysis. They reported that a cutoff WBC count of 9900/μL on POD 3 yielded a sensitivity of 41% (95% CI, 34%–49%) and a

Table 4 Literature examining the value of CRP level for predicting PICs following gastrointestinal cancer surgery

Source, y	Type of cancer	Patients, n	POD	CRP cutoff, mg/dL	Sensitivity, %	Specificity, %	AUC
Welsch <i>et al.</i> ³⁸ 2007	R	48	3	14.0	80	81	0.88
Korner <i>et al.</i> ⁴¹ 2009	CR	231	3	19.0	82	73	0.82
MacKay <i>et al.</i> ⁴⁰ 2011	CR	160	4	14.5	85	86	0.87
Warschkow <i>et al.</i> ²³ 2012	CR	1187	4	12.3	66	77	0.76
Platt <i>et al.</i> ³⁹ 2012	CR	454	3	17.0	74	75	0.80
Dutta <i>et al.</i> ⁴² 2011	EG	136	3	18.0	52	64	0.81
Warschkow <i>et al.</i> ¹⁷ 2012	EG	210	4	14.1	78	70	0.77
Shishido <i>et al.</i> ²² 2016	G	417	3	17.7	66	84	0.80
Welsch <i>et al.</i> ⁶ 2008	P	688	4	14.0	70	87	0.86
Warschkow <i>et al.</i> ¹⁶ 2012	P	280	4	18.4	50	76	0.67
Present study	P	110	3	13.2	84.6	79.4	0.82

CR, colorectal; EG, esophagogastric; G, gastric; P, pancreatic; R, rectal.

specificity of 79% (95% CI, 73%–83%) for PICs. That study suggested that the diagnostic accuracy of the WBC count was lower than that of CRP level in the present study. Procalcitonin has also been described as a promising marker to predict PICs after abdominal surgery; however, the use of this marker is controversial and associated with high costs.^{15,43} Silvestre *et al.*¹⁹ evaluated 50 patients who underwent colorectal surgery with primary anastomosis in a prospective, observational study. They evaluated both CRP and procalcitonin. They reported that procalcitonin had a lower AUC than CRP. Furthermore, unlike CRP, measurement of procalcitonin level is not widely available or well established in routine clinical practice.

There are some limitations associated with this study. First, this was a retrospective, single-center study. We cannot deny the possibility that our findings were observed by chance, and the true cutoff CRP value is unknown. Second, we evaluated PICs according to the Clavien-Dindo classification, which is different from previous studies. Considering these limitations, further studies should investigate whether early diagnostic or therapeutic approaches based on an elevated CRP level on POD 3 actually lead to earlier detection of PICs, improved outcomes, and reduced morbidity after PD.

In conclusion, this study found that measurement of the CRP on POD3 had a superior diagnostic accuracy for PICs. The cutoff value for CRP was determined to be 13.2 mg/dL and was identified as a significant independent predictive factor for PICs after PD. Our findings might help physicians predict a patient's postoperative course and facilitate decision-making regarding prompt, comprehensive clinical evaluations for PICs.

Acknowledgments

This work was supported, in part, by the Uehara Memorial Foundation and Takeda Science Foundation. The authors declare that they have no competing interests. Y.A., T.A., K.K., M. Murakawa, M.S., S.K., M.U., M. Morimoto, and S.M. conceived and coordinated the study, collected patient data, and participated in the statistical analysis; Y.A., T.A., T.O., N.Y., T.Y., Y.R., M. Masuda, and S.M. participated in preparing and drafting the manuscript; all authors read and approved the final manuscript. Y.A. and T.A. contributed equally to this article.

References

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin* 2014;**64**(1):9–29
2. McPhee JT, Hill JS, Whalen GF, Zayaruzny M, Litwin DE, Sullivan ME *et al.* Perioperative mortality for pancreatotomy: a national perspective. *Ann Surg* 2007;**246**(2):246–253
3. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA *et al.* Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. *Ann Surg* 1997;**226**(3):248–257; discussion 257–260
4. Vollmer CM Jr, Sanchez N, Gondek S, McAuliffe J, Kent TS, Christein JD *et al.* A root-cause analysis of mortality following major pancreatotomy. *J Gastrointest Surg* 2012;**16**(1):89–102; discussion 103
5. Kosaka H, Kuroda N, Suzumura K, Asano Y, Okada T, Fujimoto J. Multivariate logistic regression analysis for prediction of clinically relevant pancreatic fistula in the early phase after pancreaticoduodenectomy. *J Hepatobiliary Pancreat Sci* 2014;**21**(2):128–133
6. Welsch T, Frommhold K, Hinz U, Weigand MA, Kleeff J, Friess H *et al.* Persisting elevation of C-reactive protein after

- pancreatic resections can indicate developing inflammatory complications. *Surgery* 2008;**143**(1):20–28
7. Aoyama T, Murakawa M, Katayama Y, Yamaoku K, Kanazawa A, Higuchi A *et al.* Impact of postoperative complications on survival and recurrence in pancreatic cancer. *Anticancer Res* 2015;**35**(4):2401–2409
 8. Wu W, He J, Cameron JL, Makary M, Soares K, Ahuja N *et al.* The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. *Ann Surg Oncol* 2014;**21**(9):2873–2881
 9. van der Gaag NA, Harmsen K, Eshuis WJ, Busch OR, van Gulik TM, Gouma DJ. Pancreatoduodenectomy associated complications influence cancer recurrence and time interval to death. *Eur J Surg Oncol* 2014;**40**(5):551–558
 10. Kamphues C, Bova R, Schricke D, Hippler-Benscheidt M, Klauschen F, Stenzinger A *et al.* Postoperative complications deteriorate long-term outcome in pancreatic cancer patients. *Ann Surg Oncol* 2012;**19**(3):856–863
 11. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. *J Clin Invest* 2003;**111**(12):1805–1812
 12. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. *Clin Infect Dis* 2004;**39**(2):206–217
 13. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. *Lancet Infect Dis* 2007;**7**(3):210–217
 14. Szczepanik AM, Scislo L, Scully T, Walewska E, Siedlar M, Kolodziejczyk P *et al.* IL-6 serum levels predict postoperative morbidity in gastric cancer patients. *Gastric Cancer* 2011;**14**(3):266–273
 15. Mokart D, Merlin M, Sannini A, Brun JP, Delperro JR, Houvenaeghel G *et al.* Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major surgery. *Br J Anaesth* 2005;**94**(6):767–773
 16. Warschkow R, Ukegini K, Tarantino I, Steffen T, Muller SA, Schmied BM *et al.* Diagnostic study and meta-analysis of C-reactive protein as a predictor of postoperative inflammatory complications after pancreatic surgery. *J Hepatobiliary Pancreat Sci* 2012;**19**(4):492–500
 17. Warschkow R, Tarantino I, Ukegini K, Beutner U, Muller SA, Schmied BM *et al.* Diagnostic study and meta-analysis of C-reactive protein as a predictor of postoperative inflammatory complications after gastroesophageal cancer surgery. *Langenbecks Arch Surg* 2012;**397**(5):727–736
 18. Warschkow R, Tarantino I, Torzewski M, Naf F, Lange J, Steffen T. Diagnostic accuracy of C-reactive protein and white blood cell counts in the early detection of inflammatory complications after open resection of colorectal cancer: a retrospective study of 1,187 patients. *Int J Colorectal Dis* 2011;**26**(11):1405–1413
 19. Silvestre J, Rebanda J, Lourenco C, Pova P. Diagnostic accuracy of C-reactive protein and procalcitonin in the early detection of infection after elective colorectal surgery—a pilot study. *BMC Infect Dis* 2014;**14**:444
 20. Warschkow R, Tarantino I, Folie P, Beutner U, Schmied BM, Bisang P *et al.* C-reactive protein 2 days after laparoscopic gastric bypass surgery reliably indicates leaks and moderately predicts morbidity. *J Gastrointest Surg* 2012;**16**(6):1128–1135
 21. Adamina M, Steffen T, Tarantino I, Beutner U, Schmied BM, Warschkow R. Meta-analysis of the predictive value of C-reactive protein for infectious complications in abdominal surgery. *Br J Surg* 2015;**102**(6):590–598
 22. Shishido Y, Fujitani K, Yamamoto K, Hirao M, Tsujinaka T, Sekimoto M. C-reactive protein on postoperative day 3 as a predictor of infectious complications following gastric cancer resection. *Gastric Cancer* 2016;**19**(1):293–301
 23. Warschkow R, Beutner U, Steffen T, Müller SA, Schmied BM, Güller U *et al.* Safe and early discharge after colorectal surgery due to C-reactive protein: a diagnostic meta-analysis of 1832 patients. *Ann Surg* 2012;**256**(2):245–250
 24. Ortega-Deballon P, Radais F, Facy O, d'Athis P, Masson D, Charles PE *et al.* C-reactive protein is an early predictor of septic complications after elective colorectal surgery. *World J Surg* 2010;**34**(4):808–814
 25. Sobin LH, Gospodarowicz MK, Wittekind C. *TNM Classification of Malignant Tumours*. 7th ed. Oxford, UK: John Wiley & Sons, 2011
 26. Hayashibe A, Kameyama M, Shinbo M, Makimoto S. The surgical procedure and clinical results of subtotal stomach preserving pancreaticoduodenectomy (SSPPD) in comparison with pylorus preserving pancreaticoduodenectomy (PPPD). *J Surg Oncol* 2007;**95**(2):106–109
 27. Kimura W. Strategies for the treatment of invasive ductal carcinoma of the pancreas and how to achieve zero mortality for pancreaticoduodenectomy. *J Hepatobiliary Pancreat Surg* 2008;**15**(3):270–277
 28. Kakita A, Takahashi T, Yoshida M, Furuta K. A simpler and more reliable technique of pancreatojejunal anastomosis. *Surg Today* 1996;**26**(7):532–535
 29. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD *et al.* The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg* 2009;**250**(2):187–196
 30. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;**240**(2):205–213
 31. Liang TB, Bai XL, Zheng SS. Pancreatic fistula after pancreaticoduodenectomy: diagnosed according to International Study Group Pancreatic Fistula (ISGPF) definition. *Pancreatol-ogy* 2007;**7**(4):325–331
 32. Pratt WB, Maithel SK, Vanounou T, Huang ZS, Callery MP, Vollmer CM Jr. Clinical and economic validation of the

- International Study Group of Pancreatic Fistula (ISGPF) classification scheme. *Ann Surg* 2007;**245**(3):443–451
33. Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR *et al.* Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). *Surgery* 2007; **142**(5):761–768
 34. Kanda Y. Investigation of the freely available easy-to-use software 'EZ' for medical statistics. *Bone Marrow Transplant* 2013;**48**(3):452–458
 35. Robertson EA, Zweig MH. Use of receiver operating characteristic curves to evaluate the clinical performance of analytical systems. *Clin Chem* 1981;**27**(9):1569–1574
 36. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. *Clin Chem* 1993;**39**(4):561–577
 37. Soreide K. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. *J Clin Pathol* 2009;**62**(1):1–5
 38. Welsch T, Muller SA, Ulrich A, Kischlat A, Hinz U, Kienle P *et al.* C-reactive protein as early predictor for infectious postoperative complications in rectal surgery. *Int J Colorectal Dis* 2007;**22**(12):1499–1507
 39. Platt JJ, Ramanathan ML, Crosbie RA, Anderson JH, McKee RF, Horgan PG *et al.* C-reactive protein as a predictor of postoperative infective complications after curative resection in patients with colorectal cancer. *Ann Surg Oncol* 2012;**19**(13): 4168–4177
 40. MacKay GJ, Molloy RG, O'Dwyer PJ. C-reactive protein as a predictor of postoperative infective complications following elective colorectal resection. *Colorectal Dis* 2011;**13**(5):583–587
 41. Korner H, Nielsen HJ, Soreide JA, Nedrebo BS, Soreide K, Knapp JC. Diagnostic accuracy of C-reactive protein for intraabdominal infections after colorectal resections. *J Gastrointest Surg* 2009;**13**(9):1599–1606
 42. Dutta S, Fullarton GM, Forshaw MJ, Horgan PG, McMillan DC. Persistent elevation of C-reactive protein following esophagogastric cancer resection as a predictor of postoperative surgical site infectious complications. *World J Surg* 2011; **35**(5):1017–1025
 43. Tschakowsky K, Hedwig-Geissing M, Braun GG, Radespiel-Troeger M. Predictive value of procalcitonin, interleukin-6, and C-reactive protein for survival in postoperative patients with severe sepsis. *J Crit Care* 2011;**26**(1):54–64